-
Jan 22, 2025 | 
cfp.ca | Ricky Turgeon |James McCormack |Jen Potter
Clinical questionDoes sodium restriction improve outcomes in patients with chronic heart failure (CHF)? Bottom lineIn patients with CHF, restricting dietary sodium to less than 2 g/day does not reduce death or hospitalization compared with 2 to 3 g/day.
-
Jan 22, 2025 | 
cfp.ca | Ricky Turgeon |James McCormack |Jen Potter
Question cliniqueLa restriction du sodium améliore-t-elle les issues chez les patients atteints d’insuffisance cardiaque chronique (ICC)? RésultatsChez les patients atteints d’ICC, la restriction de l’apport alimentaire en sodium à moins de 2 g/jour ne réduit pas la mortalité ni les hospitalisations en comparaison d’un seuil de 2 à 3 g/jour. Données probantesQuatre revues systématiques ont évalué la restriction du sodium chez des patients atteints d’IC (5 à 17 ECR, 479 à 1683 participants)1-4.
-
May 14, 2024 | 
cfp.ca | Blair MacDonald |James McCormack |Ricky Turgeon
Main messageOverview of the decision aid. The decision aid is structured as 4 steps: 1) calculating risk; 2) asking what matters most to the patient; 3) selecting medication options; and 4) summarizing the discussion. These steps are intended to emulate the process of SDM and are to be used during discussions between patients and clinicians. Step 1.
-
Apr 25, 2024 | 
onlinelibrary.wiley.com | Blair MacDonald |Ricky Turgeon |James McCormack |James McCormack BSc
NARRATIVE Metformin has historically been the first-line drug option for Type 2 diabetes mellitus, likely based on the UK Prospective Diabetes Study (UKPDS-34 trial), which showed benefits in mortality and myocardial infarction with metformin compared to diet control in overweight patients.1 The finding, however, was muddied by a UKPDS substudy showing metformin increased mortality when added to a sulfonylurea.
-
Apr 16, 2024 | 
cfp.ca | Betsy Thomas |Danielle Perry |Samantha Moe |Ricky Turgeon
Main messageHow does prescribing a high-dose statin compare to a “treat-to-target” strategy in patients with coronary artery disease?
-
Dec 13, 2023 | 
cfp.ca | Blair MacDonald |Scott Garrison |Ricky Turgeon
Clinical questionDo triglyceride-lowering medications (fibrates, statins, niacin, omega-3 fatty acids) reduce the risk of pancreatitis in patients with hypertriglyceridemia? Bottom lineNo RCTs have assessed the effect of fibrates or other triglyceride-lowering medications on pancreatitis risk in patients with very high triglyceride levels (≥5.6 mmol/L).
-
Nov 24, 2023 | 
journals.sagepub.com | Blair MacDonald |Ricky Turgeon
Shared decision-making (SDM) consists of identifying a decision to be made, discussing the available options (with their associated benefits, harms and practical considerations) and eliciting patient values to arrive at a collaborative decision.1 Despite the ethical2 and empiric3 benefits of SDM, uptake of this approach remains low.4 Pharmacists are well positioned to help address such shortcomings, given their medication expertise and ever-expanding scope of practice.
-
Oct 28, 2023 | 01841-x/abstract&sz=64)
onlinecjc.ca | Kevin Bainey |Guillaume Marquis-Gravel |Emilie P Belley-Cote |Ricky Turgeon
•Current practice emphasizes consideration for maintenance of chronic ASA therapy before elective coronary angiography. For elective coronary angiography with possibility of PCI, if a patient is not on chronic ASA therapy, a loading dose of ASA is usually administered orally before the procedure. •For planned elective PCI, current practice emphasizes consideration for pre-treatment with DAPT at least 2 hours before PCI.
-
Oct 28, 2023 | 01841-x/fulltext&sz=64)
onlinecjc.ca | Kevin Bainey |Guillaume Marquis-Gravel |Emilie P Belley-Cote |Ricky Turgeon
AbstractAntiplatelet therapy (APT) is the foundation of treatment and prevention of atherothrombotic events in patients with atherosclerotic cardiovascular disease. Selecting the optimal APT strategies to reduce major adverse cardiovascular events, while balancing bleeding risk, requires ongoing review of clinical trials.
-
Oct 13, 2023 | 
cfp.ca | Blair MacDonald |Michael R Kolber |Ricky Turgeon
Clinical questionDoes influenza vaccination reduce the risk of cardiovascular (CV) events? Bottom lineFor every 100 patients vaccinated for influenza within about 1 month of an acute coronary syndrome (ACS), 2 fewer will experience CV events and 2 fewer will die at 1 year compared with placebo. The impact of influenza vaccination in primary CV prevention and other CV conditions is less clear.
